GENEMAX CORPORATION (OTCBB: GMXX) (FRANKFURT AND BERLIN EXCHANGES: GX1)

Dear Reader,

We recently profiled an intriguing company called GeneMax (OTCBB: GMXX) - which is developing a therapeutic vaccine for the treatment of cancer based on its proprietary TAP technology that restores the ability of the immune system to recognize and attack cancerous cells.  Click here to read our full profile (8/7/03)
 

**Breaking** NEWS FROM GENEMAX

Press Release
Source: Crucell N.V.
Tuesday August 12, 2:15 am ET 

LEIDEN, Netherlands, August 12, 2003 (PRIMEZONE) -- Dutch biotechnology company
Crucell N.V. (Euronext:CRXL) (NasdaqNM:CRXL - News) and US-based GeneMax Corp.
(OTC BB:GMXX.OB - News) (Frankfurt:GX1) today announced that they have entered a
license agreement for Crucell's PER.C6(TM) cell line technology. Under the terms of the agreement, GeneMax will use Crucell's PER.C6(tm) technology for research in the field of adenovirus-based gene delivery. GeneMax has also obtained an option for a non-exclusive commercial license to use PER.C6(tm) cells to manufacture and sell products in the field of gene delivery. Crucell will receive upfront and annual payments for the research license. If the research license is converted into a commercial license, Crucell will receive additional annual payments and royalties on future sales of PER.C6(TM)-derived products. Further financial details were not disclosed.

"This license represents an important building block in our program to move GeneMax's cancer vaccine into clinical trials. We perceive the Crucell vector to be the best available for delivering the TAP gene," said Ronald Handford, President & CEO of GeneMax. "We signed the first PER.C6(tm) license in 1998. Since that time PER.C6(tm) has become the 'industry standard' in the area of adenovirus-based gene delivery. Currently, six PER.C6(tm)-based products are in clinical trials," commented Dinko Valerio, Crucell's President and CEO. "As interest in gene delivery rebounds, we believe new opportunities for future agreements will further strengthen PER.C6(tm)'s value to this industry."

About Crucell

Crucell N.V. is committed to improving public health through the development of vaccines and antibodies that prevent or treat infectious diseases. Crucell develops vaccines and licenses its PER.C6(tm) production technology to companies in the pharmaceutical and biotechnology industry. The company's licensees include Merck & Co., Inc. for its HIV vaccine, Novartis, GSK, Centocor/J&J and Aventis. The company has an alliance with DSM Biologics to produce monoclonal antibodies and recombinant proteins. Crucell has partnered with the US National Institutes of Health (NIH) for the development of an Ebola vaccine. Crucell is also developing a human and veterinary West Nile vaccine based on PER.C6(tm). Crucell is headquartered in Leiden, The Netherlands, and is listed on Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information visit http://www.crucell.com.

About GeneMax

GeneMax Corp. is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer,and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection. GeneMax's lead product, the TAP (Transporters Associated With Antigen Processing) cancer vaccine is an immunotherapy for many forms of cancer, including cancers of the lung, liver, kidney, head and neck, breast, prostate, and cervix, as well as colorectal cancer and melanoma. These cancers are characterized by defects in the cellular, antigen presentation pathway, which results in the cancers becoming invisible to the immune system. GeneMax's TAP vaccine increases the activity of the antigen presentation pathway thus providing sufficient information to the immune system to cause rejection and elimination of tumors from the body. GeneMax is headquartered in Blaine, WA, USA with operations in Vancouver, Canada. For more information visit http://www.genemax.com.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 18, 2003, and the section entitled "Risk Factors."  The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For the pdf version of the press release please click on the following attachement: http://reports.huginonline.com/913256/121268.pdf

Contact:

           Crucell N.V.
           Louise Dolfing, Communications Manager
           Tel +31-(0) 71-524 8863
           l.dolfing@crucell.com

           GeneMax Corp.
           Marcus Johnson
           (866) 872-0077 or (360) 332-7734
           Fax: (360) 332-1643 
           info@genemax.com

 Source: Crucell N.V.
 

ABOUT GENEMAX CORPORATION (www.genemax.com)

GeneMax Corporation is a product-focused biotechnology company that is applying discoveries in cellular immunology and cancer biology to the development of proprietary therapeutics for cancer and immunological diseases. The Company intends to develop and bring to market novel therapeutics that treat diseases modulated by the immune system, including cancer, autoimmune diseases and transplant rejection. 

The Company's technologies are based on an understanding of the function of a protein  "pump"  within cells that is essential in the processing of tumor antigens, known as Transporters associated with Antigen Processing ("TAP").

The GeneMax core focus is on commercialization of the TAP technology as the basis for cancer vaccines. GeneMax holds the worldwide license to the patented TAP technologies that were discovered and developed by GeneMax's Chairman and Chief Science Officer, Dr. Wilfred Jefferies and his team of researchers at the University of British Columbia Biomedical Research Center. 

To view a printable GeneMax Profile in Adobe PDF format, click here.
To download a free copy of Adobe Acrobat Reader, click here.
 

GMXX SELECTED FINANCIAL HIGHLIGHTS

For a current quote on GMXX, click here.

For GMXX SEC filings, click here.
 

CONTACT

---

Want to feature YOUR company to over 1 MILLION investors?
Click here to learn more about our programs or email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been paid $15,000 by Investor Communications Inc. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.